Author: admin

Can vitamins prolong life? Possibly under certain conditions.

|

vitamins can prolong life? Possibly under certain conditions.

Friredrichsdorf, Germany, 2011- August/PRNewswire / – do can antioxidant vitamins such as vitamins C, E and provitamin to (beta-carotene), prevent cancer and other chronic diseases and prolonging life? A recent study provides evidence that vitamins could play an important role in the prevention of such diseases. For the study, the researchers examined 23.943 men and women as part of a pan-European research project for the German Cancer Research Center in Heidelberg (1). The results of the study observacionalindicaron that participants already regularly taking antioxidant vitamins before the study presented a risk clearly less of death by cancer and mortality in general than subjects who did not use vitamin supplements. Have been numerous works about the pros and cons of the vitamins and minerals as supplements to prevent diseases related to lifestyle (e.g., cancer and cardiovascular disease) or to protect against the risk of mortality in general, and today this subject continues to be cause for discussion. given that the prevention and the development of these chronic diseases están subject to many factors, is usually difficult to prove what exactly it acts preventively. Longevity is determined by the various elements that make up the lifestyle and genetic factors. The study showed that people who consume dietary supplements seem to be more aware with health and lead more active lives.

To explain the inconsistency of the studies carried out in this field, the researchers cited several reasons. In addition to the main problem posed by the difficulty of measuring or even test in clinical trials the preventive effects of micronutrients, another aspect apparently decisive is the supply situation of vitamins of the participants at the beginning of the study. According to this, an extra contribution of vitamins would not increase the preventive effect in participants who already from the beginning have an adequate supply. These supplements appear to benefit only people with deficiencies of vitamins.

Genetic factors may also affect the action and the need of vitamins. Recent studies show that people who hold certain genetic variants (poliformismos) of the enzymes responsible for the metabolism of vitamins can make use of these micronutrients only on a limited basis (2,3). Similarly, individuals who are not so unusual genetic variants have a greater need for vitamins and therefore benefit from an additional intake.

According to experts, when interpreting the results of studies that point to first view of a possible link between an increase in the intake of vitamins and adverse health effects, is essential to take into account other possible triggers and the moment in which appear the disease. In this paper, for example, participants who began taking vitamins during the study presented an increased risk of mortality. In the opinion of the researchers, this was not due to the effect of vitamins, but to the fact that these people began to take vitamin supplements only after they violently during the study, it already was too late to benefit from their potential preventive effects.

–
References:

1. Li k. et to the. Vitamin/mineral supplementation and cancer, cardiovascular, and all – cause mortality in a German prospective cohort (EPIC-Heidelberg). European Journal of Nutrition. July 2011.

2 Blum et S. to the. Vitamin E reduce cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010; 11 (5): 675-684.

3. Eric B. Rimm and Meir j Stampfer. Folate and cardiovascular diseases one size does not fi t all.

Read More

CSL Behring receives the approval of the European health authorities for the self management of Berinert (R).

|

CSL Behring receives the approval of health authorities in Europe for the self-management of Berinert r.

-esterada C1 Inhibitor self-management is already approved in 23 European countries for the treatment of hereditary angioedema, a rare condition, and sometimes deadly

Marburg, Germany, August 25, 2011- / PRNewswire / – CSL Behring announced today that the European health authorities have approved the self-management of Berinert r, a concentrate of inhibitor of esterase of C1 (C1-INH) indicated in Europe for the treatment of acute attacks of hereditary angioedema (HAE), for its acronym in English, a rare genetic disorderserious and sometimes fatal. The expanded European label allows patients to auto – manage Berinert by intravenous injection, after consultation with a doctor and after receiving the appropriate training.

“Once an attack of HAE symptoms begin to appear, any delay in the commencement of treatment can increase the severity of the attack.” This can lead to hospitalization of the patient. “However, if a patient is given treatment himself in the right way, can be avoided these and other problems”, said Associate Professor Wolfhart Kreuz M.D., of the Comprehensive Care Centre for Hereditary and Acquired Angioedema of the Goethe University Hospital in Frankfurt, Germany. “For example, auto-administrando treatment, the patient can reduce time from work or school.” “The self-management of Berinert allows an individualized, increasing patient confidence in its ability to auto-tratar his attacks of HAE and therapy to improve their quality of life.”

“With the European approval of Berinert for the self-management, doctors and patients have another important option to help reduce the suffering caused by HAE, said Henrik Boysen, executive director of HAEi, the international patient organization for C1 Inhibitor deficiencies. “It is well known that early treatment dramatically reduces the severity and duration of an attack of hereditary angioedema, and can also save the life of the patient.” “As defenders of patients around the world in HAEi we welcome this new indication of label for Berinert and hope that the self-management will be normal for the treatment of HAE, as it is to treat hemophilia, another type of rare and serious disease.”

Berinert is permitted in Europe for the treatment of HAE acute attacks in all parts of the body. Clinical studies have shown that with Berinert intervention on the occurrence of an attack of HAE is a much faster relief to a patient and reduces the severity of the attack when compared with the placebo.

“CSL Behring is delighted that the patients of HAE in Europe might already auto – manage Berinert”, said Ingolf Sieper, Executive Vice President of global business operations. “We know that the self-management of Berinert helps to restore normality and independence for patients.” “Our commitment to improve the lives of those affected by rare diseases is underlined by this good news.”

To approve the expanded label for Berinert, European authorities recognize the experience and existing clinical practice during the past 25 years, showing the safety and efficacy of the self-management of C1-INH. In 2010, medical experts in HAE published a consensus document in Allergy, Asthma and Clinical Immunology to conclude therapy and self-management in the home would HAE patients treat their symptoms more proactively in a way that will keep the safety of patients, and you minimize the inconvenience to their lives.

CSL Behring has marketed the concentrate of inhibitor of esterase Germany C for more than 30 years. In December 2008, the company completed a European Mutual Recognition Procedure (MRP) for Berinert for the treatment of acute attacks of HAE in 23 European countries and later received all respective national licences. In October 2009, the food and drugs of United States Administration adopted Berinert for treating abdominal attacks or easy acute HAE in patients adolescents and adults in United States. National marketing authorisations were granted for Berinert in Australia in January 2010, Canada in June 2010, and Israel in January 2011. CSL Behring also sells Berinert in Argentina, Japan and Switzerland.

About hereditary angioedema

The HAE is a rare genetic disorder caused by a deficiency of C1-INH. It is inherited in an autosomal dominant manner. HAE symptoms include episodes of edema or swelling, hands, feet, face, abdomen, or larynx. Patients who have abdominal attacks of HAE may experience episodes of extreme pain, diarrhea, nausea and vomiting caused by the swelling of the intestinal wall. HAE attacks involving the face and throat can result in the closure of the respiratory tract, asphyxia, and, if untreated, death. Diagnosis of HAE requires a blood test to confirm low or abnormal levels of C1-INH.

About Berinert r

Berinert r is a concentrate of inhibitor of human, highly purified plasma-derived C1 esterase. As intravenous therapy, it quickly the root cause of the symptoms of hereditary angioedema (HAE) providing patients with deficiency of C1-INH the human protein which is lacking. Berinert is a therapy of only HAE for its reliable record of efficacy and safety demonstrated in more than 30 years of international clinical use in more than 500,000 treatments.

About CSL Behring

CSL Behring is a global leader in the industry bioterapéutica of plasma proteins. Committed to saving lives and improving the quality of life of people with rare and serious diseases, the company manufactures and markets a wide range of recombinant products and derivatives of the plasma around the world. CSL Behring therapies are used in the treatment of disorders of diseases of clotting, including hemophilia, von Willebrand, primary immune deficiencies, hereditary angioedema and hereditary respiratory disease.

The company’s products are also used in cardiac surgery, organ transplantation and treatment of Burns and to prevent hemolytic disease in the newborn. The company also manages one of the largest networks in the world collection of plasma, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical based in Melbourne, Australia.

Read More

Obstructive sleep apnea can be related to the proliferation of cancer cells.

|

The obstructive sleep apnea can be related to the proliferation of cells cancerous.

the results of the study might have clinical implications in future if the data are confirmed in studies on a large scale in human

-The cancerous melanoma tumors found in an animal model of obstructive sleep apnea tend to contain more dead cells, which is associated with a type of cancer more aggressive

-the weight of the tumor and necrosis in the Group of intermittent hypoxia mice were nearly two times higher than in tumors of the Panel control.

Spain, 2011-August A new study has found clues linking the intermittent interruption of respiration that occurs in patients with obstructive sleep apnea with a greater proliferation of melanoma cells and increased tumour growth. The study with mice, also revealed that the cancer cells were found in the models with simulation of apneas contained more dead cells, suggesting that the tumour process is more aggressive.

It is the first study that concludes that a high rate of lack of oxygen, also called hypoxia, intermittent produces an increase in the growth of tumors. Hypoxia is a recurring symptom in obstructive sleep apnea and may be the cause of an increased risk of cardiovascular problems such as hypertension, in the same way that daytime sleepiness produced a low quality of life.

“Although previous studies in animals have shown that the continuing lack of oxygen plays an important role in the regulation of the various stages of formation and tumor progression, the results obtained from studies in humans including patients with apnea are not easy to interpret because there are other possible confounding factors”, especially obesity. For this reason, this study controlled in a mouse model has enabled us to ensure that the only variable in study was intermittent hypoxia ”, explains researcher Ramon Farré, Professor of the unity of Biophysics and bioengineering of the Faculty of Medicinica of the Universitat de Barcelona-IDIBAPS and member of the dream of SEPAR area.

It is well known that continuous hypoxia promotes the growth of cancer cells and tumors. However, there are no data on the effects of changes in the fast pace of the oxygenation of the cancer sleep apnea.
The results of this study could have future clinical implications if the result is confirmed in studies on a large scale in human

In this study, the mice injected with melanoma tumor cells were divided into two groups. In the first group, the mice were exposed to intermittent hypoxia that simulated of the sleep apnea, where oxygen was restricted for 20 seconds with a period of repetition of 60 cycles per hour for six hours a day, and normal levels of oxygen for the rest of the day. In the second group, the mice received normal levels of oxygen. The tumor volume was measured throughout the 14-day study. At the end of the study period, all the mice tumors were removed and heavy, and the degree of necrosis of various tumors was measured to determine the aggressiveness of different tumors found.

“ The results showed that while the volume of the tumor had steadily increased over time, both intermittent hypoxia and the control group, the increase was greater in mice subjected to hypoxia intermittent, the weight of the tumor and necrosis in the intermittent hypoxia group were almost two times the tumors in the control group ”, stated Professor Farré.

With the limitations of any studies with animal models, these results suggest that intermittent hypoxia that characterizes the obstructive sleep apnea may increase the growth of tumors. Although on the basis of previous studies that connect hypoxia continuous growth tumor outcomes were not totally unexpected, had not shown that a link there is between specific breathing abnormalities of tumor progression and sleep apnea. This work, partially funded by SEPAR, he was selected for presentation at the Symposium “ scientific discoveries of the year ” during the recently held Conference of the American Thoracic Society, and will be published in the European Respiratory Journal.

A line of future research would be to assess if the intermittent hypoxia also causes the initial formation of tumors and promotes metastasis of tumors of a body to another. Extensive epidemiological studies may also determine if there is a relationship between cancer incidence and severity of apnea. It is also known that obesity increases morbidity and mortality from cancer, and is not clear to what extent the intermittent hypoxia and obesity, very present in patients with sleep apnea, can interact to increase cancer in patients with apnea.

As indicated by Dr. Josep Maria Montserrat of the Hospital Clínic of Barcelona and coordinator of the research programme integrated dream of SEPAR, co researcher of the study, additional studies are needed to clarify these issues without a doubt. If the current results in an animal model is confirmed by additional clinical research, the impact on public health of the obstructive sleep apnea may be larger than is currently known.

Read More

The intelligent weight loss system management (TM) (the intelligent management of thinning) of my.abiliti (R) combines advanced technology and useful to its members support.

|

Intelligent weight loss system (TM) management (intelligent management of thinning) of my.abiliti (R) combines advanced technology and useful for its members support

launch of a portal of entry of personal data and a community of patients in line during the Congress World of the Federation International of surgery of the obesity.

Mountain View (California, United States), 2011-August IntraPace, Inc., producer of the innovative implantable system for the treatment of obesity abiliti ®, has launched last Saturday his new lifestyle and support network management portal this week during the 16th Congress World of the Federation International of surgery for obesity and the metabolic disorders (IFSO) in Hamburg (Germany). my.abiliti® is a resource exclusive Internet allowing users to control their personal behaviour as regards food and exercise, scoring goals and get them, receive individual tutoring, access to educational resources and benefit from a valuable network of support. According to its own decision, the user can share experiences and personal achievements with friends, family and other members as well as experienced practitioners of health care.

The abiliti ® system is a new implantable device that uses patented sensors to detect food intake to initiate a gastric stimulation that makes that patients be filled earlier than normal. In addition, it automatically logs information on intakes, as well as the frequency and duration of the exercise carried out. The my.abiliti portal is the only site and online community that you can use objective behavior data, collected and stored by the device abiliti and recovered by wireless means with head connect.abiliti. This information enables intelligent thinning based on regular self-monitoring.

“several studies have shown that a solid support system is essential to achieve a healthy weight loss long term.” «Advanced technology that underpins my.abiliti.com can provide an unprecedented level of support to its users», said Chuck Brynelsen, President and CEO of IntraPace. “We encourage all of our patients to join this online community so that they can exchange information, share their progress and access to exclusive training and mentoring that offer recognised experts in the treatment of overweight”.

IntraPace carried out individual demonstrations of my.abiliti in his stand during the Congress IFSO 2011. You are expected to attend the Congress over 2000 major specialized in obesity surgeons and other professionals of the health of everyone.

For more information about the system abiliti or attend a free demo of the portal and social network for treatment of my.abiliti weight, visit IntraPace Congress IFSO. The stand of IntraPace will be on the space number 24 of the H flag in the center of congresses of Hamburg (CCH).

About the abiliti system

After its introduction through simple surgery minimally invasive abiliti system detects the person eats or drinks and sends low-level electrical impulses to the stomach. This stimulation is intended to help you feel satiated before the stomach is full indeed, causing so you eat less. As it does not alter the anatomy of the stomach or intestines, clinical experience with the abiliti system demonstrated the almost total absence of nausea, diarrhea, and other side effects that occur with surgery gastric bypass and gastric cerclage. Patients have no restrictions on the types of food can be consumed, but are encouraged to adopt a healthy diet and exercise program.

In addition, this system automatically logs if the patient eats, drinks, or exercising. Through a simple wireless connection, the doctor and the patient can see data on consumption and exercise. Access to this information represents a huge advantage since it allows them to understand both the behaviour of the patient, as well as to develop effective strategies for achieving weight loss and keep it. Moreover, the system offers patients contact with a valuable social support network, as evidenced by the investigations, can increase the efficiency of slimming programmes.

About IntraPace

IntraPace was founded in 2001 to address a need not met in the field of Bariatric Surgery through the development of a more acceptable solution for weight loss that it incorporates essential components of behavioral therapy. The abiliti system is designed to facilitate that patients achieve and maintain weight loss considerable without complications, the limitations of the lifestyle and the substantial anatomical changes that involve traditional bariatric surgery procedures.

IntraPace headquartered in Mountain View (California) and has the backing of major investors, which include Boston Scientific, CB Health Ventures, DFJ ePlanet Ventures, linger Ventures, Johnson & Johnson Development Corp., L Capital Partners, Oxford Bioscience Partners, Toucan Capital Corp, Angels ’ Forum, Halo Fund and Vulcan Capital.

The System abiliti has the CE mark in the European Union. You are not authorized for sale in the United States.

Read More

Cancer that changed history. Famous patients who have suffered head and neck cancer

|

cancer that changed history.

Famous patients who have suffered from cancer of head and neck

-head and neck cancer is one of the strangers of all cancers, but is the fourth most common tumor in men.

– by medical personnel may exist certain prejudices in how to handle them, and may not be deposited in them all the confidence in their collaboration, and this may even help that don’t gamble by ambitious treatments with aim healing.

-historical characters relevant as the kaiser Frederick III, Sigmund Freud or Beatle George Harrison suffered head and neck cancer. A review of your medical history and personal and social impact which this cancer in these characters helps the oncologist to understand this disease in a way more humanist.

Madrid, 2011-August When affected by disease is a known character, the interest in the disease increases exponentially among the general population. In regards to oncology, tumors with high incidence affected celebrities — such as breast, lung, colon and prostate — have often contributed to a greater general awareness. However, very rarely refers to characters who have suffered head and neck cancer, that there have been many and very relevant.

“ As a paradoxical exception, and although it shares similar risk factors with lung cancer, head and neck cancer continues to be little known, and in fact, arguably it is a tumor that ‘ socially ’ there is almost no ”, points out Dr. Javier Martinez Trufero, oncologist Hospital Miguel Servet in Zaragoza.

“ May exist certain prejudices among the medical community in the approach of this group of patients, not always with the disease as a result of preventable factors (alcohol or tobacco), and even if it is for these reasons, they deserve the same effort than any other type of cancer patient, to achieve the most ambitious therapeutic results ” adds Dr. Martínez Trufero ”.

This situation has led to the birth of an initiative — developed by the chemical company pharmaceutical German Merck and supported by a group of oncologists in the Spanish research group in cancer of head and neck (TTCC) — which is based on a series of publications designed to publicize how this not only cancer affects to a minority social group, but that can affect anyone. Throughout history this cancer has changed even the history or has had an important role in it.

An example is the cancer of the larynx which caused the death of kaiser Frederick III and led to the accession to the throne of Prussia of his son and successor William II, era that marked the beginning of an era of confrontation begins with World War I.

Another example is that of Beatle George Harrison with a cancer of the oral cavity joined other lung, which caused his early death at the age of 58.

A tumor of palate, result of his habit of CHD, also cost the lives of Sigmund Freud, father of psychoanalysis, died at the age of 83 after a long process of evolutionary, usual in this type of tumor. Much of his work could be very influenced by his illness.

“ Highlight the relevance of head and neck cancers has been throughout history is the goal of this series of patobiografías, claiming to give to know from a human point of view which means this disease, and promote the interest in this pathology of all professionals involved in your treatment. We hope that, through these relevant historical examples, we can help to stimulate the knowledge and research about these tumors, and contribute to humanising over our work. ”, concludes Dr. Martinez Trufero.

Three patobiografías have been published so far:

• cancer that changed history. Frederick III of Germany
• the quiet Beatle. George Harrison
• oral cancer. Sigmund Freud

in the coming months, the collection will continue with:

• Ulysses S. Grant. US President
• Giacomo Puccini. Composer

about Merck and the Merck Serono Division

Merck, the multinational German with major pharmaceutical and chemical tradition of the world, is today a company with sales of 9,300 euros million in 2010. With a history that goes back to 1668 and a success based on innovations developed by contributors with an entrepreneurial spirit, Merck has today with around 40,000 employees in 67 countries worldwide. Focused on two sectors of business – the pharmacist and chemist – all the activity of the company is organized around four divisions: Merck Serono and Merck Consumer Health Care (pharmaceuticals); and Merck Millipore and Performance Materials (chemical sector). Merck brings together its activities under Merck KGaA, whose shares belong to the Merck family 70% approximately. The remaining 30% is listed on the stock exchange.

Merck Serono is the Division of Merck biopharmaceutical. With sales of 5.7 billion euros and an investment in r & d of more than 1.1 billion euros in 2010, Merck Serono is committed to grow your business in the current therapeutic areas (Oncology, autoimmune and inflammatory diseases, cardiometabolismo, fertility and neurodegenerative diseases), as well as developing new areas that may arise from the r & d, as the Rheumatology.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips